The Wet Age-Related Macular Degeneration (Wet AMD) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Wet Age-Related Macular Degeneration (Wet AMD): An Overview
According to American Macular Degeneration Foundation, Wet Age-Related Macular Degeneration (Wet-AMD) is a type of macular degeneration in which abnormal blood vessels (known as choroidal neovascularization or CNV) develop under the retina and macula. These abnormal blood vessels often grow and leak or bleed, causing scarring of the macula. This damage to the macula results in rapid central vision loss. Once this vision is destroyed, it cannot be restored. Wet AMD results in the exudation or leakage of fluid and blood from new blood vessels and is also called neovascular AMD or exudative AMD.
Wet Age-Related Macular Degeneration (Wet AMD) Market Key Facts
As per the DelveInsight, females are affected more as compared to males, in the case of Wet AMD.
Nearly 11 million Americans have some form of macular degeneration, while 1.1 million or 10% of those Americans have wet AMD.
As per the National Eye Institute (NEI), in 2010, 65 per cent of total AMD cases were in women as compared to 35 percent in men.
The wet/neovascular type affects approximately 10-15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease.
Get FREE sample copy at: Wet Age-Related Macular Degeneration (Wet AMD) Therapeutics Market
Key Benefits of Wet Age-Related Macular Degeneration (Wet AMD) Market Report
The report provides an in-depth analysis of Wet Age-Related Macular Degeneration (Wet AMD) Market Size and Share till 2030 in the seven major markets.
The report will help in developing business strategies by understanding the Wet Age-Related Macular Degeneration (Wet AMD) Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
It covers Wet Age-Related Macular Degeneration (Wet AMD) current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
The report provides a detailed assessment of the Wet Age-Related Macular Degeneration (Wet AMD) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Wet Age-Related Macular Degeneration (Wet AMD) Market
Technological advancements, upcoming treatment options, along with increasing research initiatives regarding wet AMD, are expected to stimulate the Wet Age-Related Macular Degeneration (Wet AMD) market growth in the coming years.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Wet Age-Related Macular Degeneration (Wet AMD) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Wet AMD market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Wet Age-Related Macular Degeneration Epidemiology
The epidemiology section covers insights about the historical and current Wet AMD patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Wet Age-Related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Wet Age-Related Macular Degeneration (Wet AMD) market or expected to get launched in the market during the study period. The analysis covers Wet AMD market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Wet Age-Related Macular Degeneration Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Wet Age-Related Macular Degeneration Therapeutics Analysis
Key companies in the Wet Age-Related Macular Degeneration (Wet-AMD) market include:
Allergan
Bioeq GmbH
Alkahest
Graybug Vision
Eye point pharma
Regeneron Pharmaceuticals
And others.
Wet Age-Related Macular Degeneration Therapies covered in the report includes:
Abicipar-pegol
FYB201
AKST4290
GB-102
Vorolanib
Eylea
And many others.
Request for Sample @ Wet Age-Related Macular Degeneration (Wet AMD) Emerging Therapies and Key Companies
Table of Content
1. Key Insights
2. Executive Summary
3. Wet Age-Related Macular Degeneration (Wet AMD) Competitive Intelligence Analysis
4. Wet Age-Related Macular Degeneration (Wet AMD) Market Overview at a Glance
5. Wet Age-Related Macular Degeneration (Wet AMD) Disease Background and Overview
6. Wet Age-Related Macular Degeneration (Wet AMD) Patient Journey
7. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology and Patient Population
8. Wet Age-Related Macular Degeneration (Wet AMD) Treatment Algorithm, Current Treatment, and Medical Practices
9. Wet Age-Related Macular Degeneration (Wet AMD) Unmet Needs
10. Key Endpoints of Wet Age-Related Macular Degeneration (Wet AMD) Treatment
11. Wet Age-Related Macular Degeneration (Wet AMD) Marketed Products
12. Wet Age-Related Macular Degeneration (Wet AMD) Emerging Therapies
13. Wet Age-Related Macular Degeneration (Wet AMD) Seven Major Market Analysis
14. Attribute Analysis
15. Wet Age-Related Macular Degeneration (Wet AMD) Market Outlook (7 major markets)
16. Wet Age-Related Macular Degeneration (Wet AMD) Access and Reimbursement Overview
17. KOL Views on the Wet Age-Related Macular Degeneration (Wet AMD) Market.
18. Wet Age-Related Macular Degeneration (Wet AMD) Market Drivers
19. Wet Age-Related Macular Degeneration (Wet AMD) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
